Drug Profile
LCP 3301
Alternative Names: LCP-3301Latest Information Update: 08 Jul 2011
Price :
$50
*
At a glance
- Originator LifeCycle Pharma
- Developer Veloxis Pharmaceuticals
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 09 Apr 2010 LCP 3301 is still in phase I trials for Transplant rejection (prevention) in Denmark